- Market Capitalization, $K 13,599,549
- Shares Outstanding, K 111,490
- Annual Sales, $ 74,910 K
- Annual Income, $ -761,500 K
- 60-Month Beta 2.47
- Price/Sales 182.13
- Price/Cash Flow N/A
- Price/Book 8.49
|Period||Period Low||Period High||Performance|
| || |
+29.92 (+32.50%)since 11/05/19
| || |
+38.83 (+46.70%)since 09/05/19
| || |
+43.62 (+55.67%)since 12/04/18
In 5 years, you be selling your gold and buying more companies leading the century of biology.
Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $119.90 to a high of $122.40. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high...
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Why Gold is Headed to Zero -- And What You Should Buy Instead
As of late, it has definitely been a great time to be an investor in Alnylam Pharmaceuticals, Inc. (ALNY).
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
SmarTrend identified an Uptrend for Alnylam Pharmace (NASDAQ:ALNY) on October 21st, 2019 at $85.25. In approximately 1 month, Alnylam Pharmace has returned 31.24% as of today's recent price of $111.88....
Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $110.74 to a high of $116.50. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high...
The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
|Ishares Genomics Immunology and Healthcare ETF|
|Bioshares Biotech Products|
|Biotech Vaneck ETF|
|Principal Healthcare Innovators Index|
|S&P Biotech SPDR|